ADD
- Manufacturer
- Apotheca Company
- Effective date
- 2022-03-28
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 4
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 22:04:51
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
ACTIVE INGREDIENTS: Gamma-aminobutyric acid 6X, 12X, 30X, 12C, 30C, L-dopa 6X, 12X, 30X, 12C, 30C, Norepinephrine 6X, 12X, 30X, 12C, 30C, Serotonin 6X, 12X, 30X, 12C, 30C, Adrenocorticotropin 8X, 12X, 30X, 12C, 30C, Anacardium orientale 30X, Arsenicum album 30C, Baryta carbonica 30C, Calcarea carbonica 30C, Calcarea phosphorica 30C, Hyoscyamus niger 30C, Lycopodium clavatum 30C, Stramonium 30C.
OTC - PURPOSE SECTION
INDICATIONS: For temporary relief of symptoms of Attention Deficit Disorder, learning disabilities and hyperactivity.
DOSAGE & ADMINISTRATION SECTION
SUGGESTED USE: Adults and children 5 to 10 drops orally, 1 to 2 times daily or as otherwise directed by a health care professional. If symptoms persist, consult your health care professional. Consult a physician for use in children under 12 years of age.
INACTIVE INGREDIENT SECTION
INACTIVE INGREDIENTS: Demineralized water, 20% Ethanol
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN. In case of overdose, get medical help or contact a Poison Control Center right away.
INDICATIONS & USAGE SECTION
INDICATIONS: For temporary relief of symptoms of Attention Deficit Disorder, learning disabilities and hyperactivity.
OTC - QUESTIONS SECTION
Dist. by Energique, Inc.
201 Apple Blvd.
Woodbine, IA 51579
800-869-8078
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
ENERGIQUE
ADD HP
Homeopathic Remedy
1 fl. oz. (30 ml)
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 57520-0356-1 | 2022-03-30 | C162847 | 48780-1 | 9d75b9d0-039d-f424-e053-dadaa90a57ce | ADD HP |
| 57520-0356-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-039d-f424-e053-dadaa90a57ce | ADD HP |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| .GAMMA.-AMINOBUTYRIC ACID | ACTIVE INGREDIENT | 2ACZ6IPC6I | 3 | |
| ARSENIC TRIOXIDE | ACTIVE INGREDIENT | S7V92P67HO | 3 | |
| BARIUM CARBONATE | ACTIVE INGREDIENT | 6P669D8HQ8 | 3 | |
| CORTICOTROPIN | ACTIVE INGREDIENT | K0U68Q2TXA | 3 | |
| DATURA STRAMONIUM | ACTIVE INGREDIENT | G6W4F0V8Z3 | 3 | |
| HYOSCYAMUS NIGER | ACTIVE INGREDIENT | 4WRK2153H3 | 3 | |
| LEVODOPA | ACTIVE INGREDIENT | 46627O600J | 3 | |
| LYCOPODIUM CLAVATUM SPORE | ACTIVE INGREDIENT | C88X29Y479 | 3 | |
| NOREPINEPHRINE | ACTIVE INGREDIENT | X4W3ENH1CV | 3 | |
| OYSTER SHELL CALCIUM CARBONATE, CRUDE | ACTIVE INGREDIENT | 2E32821G6I | 3 | |
| SEMECARPUS ANACARDIUM JUICE | ACTIVE INGREDIENT | Y0F0BU8RDU | 3 | |
| SEROTONIN | ACTIVE INGREDIENT | 333DO1RDJY | 3 | |
| TRIBASIC CALCIUM PHOSPHATE | ACTIVE INGREDIENT | 91D9GV0Z28 | 3 | |
| .GAMMA.-AMINOBUTYRIC ACID | ACTIVE MOIETY | 2ACZ6IPC6I | 3 | |
| ARSENIC TRIOXIDE | ACTIVE MOIETY | S7V92P67HO | 3 | |
| BARIUM CATION | ACTIVE MOIETY | V645272HLN | 3 | |
| CALCIUM CATION | ACTIVE MOIETY | 2M83C4R6ZB | 3 | |
| CORTICOTROPIN | ACTIVE MOIETY | K0U68Q2TXA | 3 | |
| DATURA STRAMONIUM | ACTIVE MOIETY | G6W4F0V8Z3 | 3 | |
| HYOSCYAMUS NIGER | ACTIVE MOIETY | 4WRK2153H3 | 3 | |
| LEVODOPA | ACTIVE MOIETY | 46627O600J | 3 | |
| LYCOPODIUM CLAVATUM SPORE | ACTIVE MOIETY | C88X29Y479 | 3 | |
| NOREPINEPHRINE | ACTIVE MOIETY | X4W3ENH1CV | 3 | |
| OYSTER SHELL CALCIUM CARBONATE, CRUDE | ACTIVE MOIETY | 2E32821G6I | 3 | |
| SEMECARPUS ANACARDIUM JUICE | ACTIVE MOIETY | Y0F0BU8RDU | 3 | |
| SEROTONIN | ACTIVE MOIETY | 333DO1RDJY | 3 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 3 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Products#
Every source-derived product name is available through these pages.
- ADD HP
- Gamma-aminobutyric acid, L-dopa, Norepinephrine, Serotonin, Adrenocorticotropin, Anacardium orientale, Arsenicum album, Baryta carbonica, Calcarea carbonica, Calcarea phosphorica, Hyoscyamus niger, Lycopodium clavatum, Stramonium
- .GAMMA.-AMINOBUTYRIC ACID
- NOREPINEPHRINE
- SEROTONIN
- SEMECARPUS ANACARDIUM JUICE
- ARSENIC TRIOXIDE
- ARSENIC CATION (3+)
- BARIUM CARBONATE
- BARIUM CATION
- OYSTER SHELL CALCIUM CARBONATE, CRUDE
- TRIBASIC CALCIUM PHOSPHATE
- CALCIUM CATION
- HYOSCYAMUS NIGER
- LYCOPODIUM CLAVATUM SPORE
- DATURA STRAMONIUM
- WATER
- ALCOHOL
- CORTICOTROPIN
- LEVODOPA
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 57520-0356 | 57520-0356-1 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| .GAMMA.-AMINOBUTYRIC ACID | 2ACZ6IPC6I | ACTIB |
| NOREPINEPHRINE | X4W3ENH1CV | ACTIB |
| SEROTONIN | 333DO1RDJY | ACTIB |
| SEMECARPUS ANACARDIUM JUICE | Y0F0BU8RDU | ACTIB |
| ARSENIC TRIOXIDE | S7V92P67HO | ACTIB |
| BARIUM CARBONATE | 6P669D8HQ8 | ACTIB |
| OYSTER SHELL CALCIUM CARBONATE, CRUDE | 2E32821G6I | ACTIB |
| TRIBASIC CALCIUM PHOSPHATE | 91D9GV0Z28 | ACTIM |
| HYOSCYAMUS NIGER | 4WRK2153H3 | ACTIB |
| LYCOPODIUM CLAVATUM SPORE | C88X29Y479 | ACTIB |
| DATURA STRAMONIUM | G6W4F0V8Z3 | ACTIB |
| WATER | 059QF0KO0R | IACT |
| ALCOHOL | 3K9958V90M | IACT |
| CORTICOTROPIN | K0U68Q2TXA | ACTIB |
| LEVODOPA | 46627O600J | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TRANSDERMAL | 90 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / ORAL | 681 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CONCENTRATE / BUCCAL | 679 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | ELIXIR / ORAL | 13675 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, EMULSION / INTRAVENOUS | 520 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / INTRAVENOUS | 4000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TOPICAL | 541 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / OPHTHALMIC | 0.5 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, METERED / NASAL | 70 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, FOAM / TOPICAL | 4504 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / TRANSDERMAL | 7360 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / RESPIRATORY (INHALATION) | 0.08 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CONCENTRATE / ORAL | 198 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CAPSULE / ORAL | 882 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / RESPIRATORY (INHALATION) | 35.75 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / ORAL | 150.68 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / INTRAVENOUS | 400 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY, METERED / SUBLINGUAL | 29 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / DENTAL | 12.8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / INTRAVENOUS | 6405 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | DROPS / ORAL | 210 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / INTRAVENOUS | 99 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / TOPICAL | 9971 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / NASAL | 10 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SWAB / TOPICAL | 2250 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL / NASAL | 20 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LOTION / TOPICAL | 25 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / NASAL | 20 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / TOPICAL | 561 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TOPICAL | 2445 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / INTRAMUSCULAR | 400 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | DROPS / NASAL | 10 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TRANSDERMAL | 49.37 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / SUBCUTANEOUS | 149 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / ORAL | 6624 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / INTRAVESICAL | 7892 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / SUBLINGUAL | 397 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SHAMPOO / TOPICAL | 714 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | MOUTHWASH / BUCCAL | 200 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TOPICAL | 3633 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | TABLET, DELAYED RELEASE / ORAL | NA | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / DENTAL | 1.8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TRANSDERMAL | 3675 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | PASTE / DENTAL | 1.8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / RESPIRATORY (INHALATION) | 5 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL / TOPICAL | 561 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAVENOUS | 92 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / ORAL | 3563 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAMUSCULAR | 1491 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SYRUP / ORAL | 21000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | POWDER, FOR SOLUTION / TOPICAL | 40 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / SUBCUTANEOUS | 6.1 %v/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / RECTAL | 898 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAVASCULAR | 100 %v/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, METERED / RESPIRATORY (INHALATION) | 26664 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / RECTAL | 0.35 %v/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / INTRAMUSCULAR | 1000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | JELLY / VAGINAL | NA |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 233690b8-78f6-4be6-85db-4c6d3ab21753 | f075a58f-2977-44b4-838d-a24ae0bc550c | 2022-03-28 | 233690b8-78f6-4be6-85db-4c6d3ab21753 f075a58f-2977-44b4-838d-a24ae0bc550c |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
